An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
| Alexander Khalessi Named President-Elect of Congress of Neurological Surgeons
UC San Diego, Department of Neurological Surgery Chair Alexander A. Khalessi, M.D., M.B.A. has been named 2023 President-Elect of the Congress of Neurological Surgeons (CNS), the leading academic society for neurosurgical professionals with more than 10,000 members worldwide.
A globally recognized board-certified neurosurgeon, Professor Khalessi specializes in complex cranial and endovascular neurosurgery for the treatment of cerebrovascular and oncologic conditions. He became chair of neurosurgery at UC San Diego in 2018 and was named the inaugural Don and Karen Cohn Chancellor’s Endowed Chair in 2021.
|
|
|
|
Theresa Guo, M.D. Awarded 2022 V Scholar Grant
Dr. Guo has been awarded a 2022 V Foundation, V Scholar Grant for her project, Defining the relationship between aberrant splicing burden and anti-tumoral immunity in head and neck squamous cell carcinoma. Congratulations, Dr. Guo!
|
|
|
| | UCSD Center for Engineering in Cancer Launched
Nicole Steinmetz, Ph.D. and Ezra Cohen, M.D., FRCPSC, FASCO have been named Co-Directors of the UCSD, Center for Engineering in Cancer.
|
|
|
Highlights from The Cancer Letter |
NCI Directors Report - Dr. Douglas Lowy: NCI to focus on multi-cancer detection tests, diversity in workforce, and clinical trials
Read full article on page 18 of The Cancer Letter, volume 48, number 32.
|
|
|
|
Department of Pharmacology, Fall 2022 Seminar Series
Metabolic Stress and the Tumor Ecosystem: New Paradigms for Tumor Progression and Therapy
Tuesday, November 1, 2022 at 12:00 p.m. PT
In-Person (Webinar option listed below)
Leichtag Biomedical Research Building (Room 107)
Cosimo Commisso, Ph.D.
Director and Associate Professor
Cell and Molecular Biology of Cancer Program
NCI-Designated Cancer Center
Sanford Burnham Prebys Medical Discovery Institute
Hosted by Andrew Lowy, M.D., FACS
|
|
|
|
UCSD Moores Cancer Center Joint Distinguished Scientist Seminar Series/Cancer Therapeutics Training Program CT2 Lecture
Mutations in Normal Cells
Monday, November 21, 2022 at 12:00 p.m. PT
Moores Cancer Center, Goldberg Auditorium, 2nd Floor
Zoom Link
Meeting ID: 874 8822 3587
Password: 419961
Professor Sir Mike Stratton, FMedSci, FRS
Director of the Wellcome Sanger Institute Chief Executive Officer Wellcome Genome Campus Cambridge, UK
Hosted by Ludmil B. Alexandrov, Ph.D.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
New Community Outreach and Engagement (COE) Newsletter
We are thrilled to share our first quarterly COE newsletter! Please take a moment to read Elena Martinez's welcome message and make a note of COE resources and upcoming events.
|
| |
Get Screened California: Increasing Lung Cancer Screening Virtual Forum
November 10, 2022, from 12:00 p.m. to 2:30 p.m.
The American Cancer Society (ACS) and the California Dialogue on Cancer (CDOC) are pleased to invite you to register for the Get Screened California: Increasing Lung Cancer Screening Virtual Forum on Thursday, November 10, from 12:00 p.m. to 2:30 p.m.
The forum is part of ACS’s partnership with CDOC to increase cancer screening rates among members of California’s diverse population. Given the high mortality rate from lung cancer and California’s lung cancer screening rates being among the lowest in the county, this year we have chosen to emphasize lung cancer screening.
We welcome healthcare, public health, and community outreach professionals to join this informative forum. Participants will learn about the current state of lung cancer screening in the United States and California, become familiar with the role they can play in increasing lung cancer screening rates, and hear innovative strategies to increase lung cancer screening. All those who can help reach local communities in California to increase lung cancer screenings are encouraged to attend this statewide forum!
|
|
|
| CT2 2022-2023 Lecture Series
Actionable Systems Biology of Small Cell Lung Cancer: Broad Implications for Tumor Plasticity
Monday, October 24, 2022 from 12:00 p.m. to 1:00 p.m.
In-Person and Virtual
Comer Commons
Zoom Link
Lunch will be provided to those who attend in person.
Vito Quaranta, M.D.
Professor of Biochemistry and Pharmacology
Director, Vanderbilt Quantitative Systems Biology Center
Following the lecture, a special Coffee, Cookies, and Conversation session with Dr. Quaranta will be held from 1:00 p.m. to 1:45 p.m. in Comer Commons for interested students and trainees to ask questions.
|
|
|
|
CT2 2022-2023 Lecture Series
Illuminating Nerves—Preserving Function
Monday, October 31, 2022 from 12:00 p.m. to 1:00 p.m.
In-Person and Virtual
Comer Commons
Zoom Link
Lunch will be provided to those who attend in person.
Quyen Nguyen, M.D.
Otolaryngologist-Head and Neck Surgeon
Professor of Surgery
UC San Diego
|
|
|
|
CT2 2022-2023 Lecture Series
Control of Pancreatic Cancer Malignancy and Patient Survival by Collagen Metabolism
Monday, November 7, 2022 from 12:00 p.m. to 1:00 p.m.
In-Person and Virtual
Comer Commons
Zoom Link
Lunch will be provided to those who attend in person.
Michael Karin, Ph.D.
Distinguished Professor of Pharmacology and Pathology
UC San Diego
PI, NCI Center for Cancer Systems Biology
Vanderbilt University
|
|
|
Student Volunteers Available
Cancer Research, Training, and Education Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu), if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop
November 10, 2022 from 12:00 p.m. to 1:00 p.m.
This is an opportunity for trainees and junior faculty to network and ask questions about career paths, scientific progress, and healthcare organizational culture.
Please pass this opportunity to your trainees (undergraduates, graduate students, medical students, postdocs) and encourage them register at the link below.
|
|
|
Speed Mentoring Faculty Sign Ups
Faculty Members of the Moores Cancer Center (MCC) are invited to serve a mentors at the MCC Cancer Research, Training, and Education Coordination (CRTEC) Speed Mentoring Workshops, which serve not only undergraduate, graduate, and post-graduate students, but also project scientists, and research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
St. Baldrick's Pediatric Cancer Awards
Scholar awards: up to $110K/year for 2 years, with potential for an additional 3 years
International Scholar awards: up to $110K/year for 3 years
Research awards: up to $100K for 1 year with possibility of $100K for second year; Institutional overhead is not allowed
The St. Baldrick's Foundation is a volunteer and donor powered charity committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives. Since awarding its first grants as an independent charity in 2005, St. Baldrick's has invested more than $322 million in childhood cancer research worldwide. UC San Diego may submit one LOI in each award category listed below. PI proposals targeting other areas of scientific interest may qualify for an exception to the categories listed below.
|
- St. Baldrick's Scholar (Career Development) Award
-
This is an early-career award intended to develop the independent pediatric cancer research careers of highly qualified investigators. Applicants should hold a Ph.D., M.D., or D.O. and be within the first 7 years of their initial independent full-time faculty appointment at the time the award begins.
- St. Baldrick's International Scholar Award
- This 3-year award, with an option for 2 additional years, based on progress, will train researchers from low-and middle-income countries (as classified by the World Bank) to fill specific stated needs in an area of childhood cancer research upon returning to their country of origin. The research proposal must include (1) 2–3 years of training at the sponsoring institution (UC San Diego) and (2) the implementation of a carefully constructed research project at the institution of origin.
- Research Grant
- These grants are for specific 1-year research projects that are hypothesis driven and may be either laboratory, clinical, or epidemiological in nature. The average grant award will be $100,000 or less.
|
Internal Submission Deadline: Tuesday, November 1, 2022 at 5:00 p.m.
Funding Organization's Deadline: Friday, December 2, 2022
|
| |
Department of Defense (DoD) Breast Cancer Research Program (BCRP), Clinical Research Extension Award (CREA)
Three expected awards; estimated total program funding $26,400,000
The FY22 DoD BCRP CREA aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. The goal of this award is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis. Although not all-inclusive, research proposed under the FY22 BCRP CREA may entail (1) a deeper molecular analysis of clinical samples, (2) initiation of new correlative studies or biomarker validation, or (3) continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing/generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, which include patient-derived models or tissue arrays. The award may not be used to directly support a clinical trial.
Deadline: December 13, 2022
|
|
|
Advancing Head and Neck Cancer Early Detection Research (AHEAD)
Maximum funding $500,000 direct costs/year for 5 years.
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions. A better understanding of the molecular characteristics of dysplastic lesions and early recurrence is needed for improving lesion classification relevant to predicting cancer progression, which could substantially improve cancer prevention and treatment optimization.
Deadline: January 27, 2023 at 5:00 p.m.
|
|
|
American Cancer Society (ACS) Request for Applications (RFA): Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
Purpose: The development of the palliative medicine speciality is a necessary step in addressing the unmet needs of both patients with serious illness and their families.
Pilot data typically are needed before funding agencies (e.g., NIH, VA, and ACS) will consider funding a research project. To support clinician investigators conducting patient-oriented research in palliative care, the ACS, in parallel with the National Palliative Care Research Center (NPCRC), is soliciting applications for pilot/exploratory research grants in palliative care for cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator's chances of successfully competing for larger grants.
This RFA is limited to applications that feature palliative care research projects for seriously ill cancer patients and their families in the following three areas:
|
-
Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
- Studying methods of improving communication between cancer survivors living with serious illness with their families and health care providers;
-
Evaluating models and systems of care for patients living with advanced illness and their families.
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Genomic Curriculum Development for Medical Students (R25)
Applications may request up to $150,000 in direct costs per year and need to reflect the actual needs of the proposed project. Applications may request award project periods of up to 3 years.
This National Human Genome Research Institute (NHGRI) R25 program supports the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine, and/or genomic informatics for medical students. The curricula should be freely available, at no cost to the broader community, to enhance training of medical students to enter the genomics workforce. The programs must be self-sustaining at the end of the award period.
This FOA will support U.S. domestic medical or osteopathic schools to develop an M.S. curriculum for educating medical students (M.D. or D.O.) in genomics. This curriculum is expected to enhance the knowledge and ability to educate future physicians to apply genomics to their research and patient care.
Deadline: October 27, 2022 at 5:00 p.m.
|
|
|
Toxic Exposures Research Program (TERP), Investigator-Initiated Research Award (IIRA)
Award: $500,000 total in direct costs
The TERP is a new Department of Defense (DoD), Congressionally Directed Medical Research Program (CDMRP) that will enable the research community to (1) improve the scientific understanding of pathobiology from toxic exposures, (2) more efficiently assess comorbidities, and (3) accelerate the development of treatments, cures, and preventions. This is a fiscal year 2022 (FY22) funding opportunity.
The DoD TERP IIRA supports studies that will make an important contribution toward research and/or patient care for a disease or condition related to toxic exposures. Research projects may address any phase of research from basic laboratory research through translational research, which includes not only preclinical studies in animal models and human subjects, but also correlative studies associated with an existing clinical trial.
Deadline: November 3, 2022 at 5:00 p.m. ET
|
|
|
Toxic Exposures Research Program (TERP), Translational Research Award (TRA)
Award: $800,000 total in direct costs (with Partnering Principal Investigator Option - $1.6M total in direct costs)
The TERP is a new Department of Defense (DoD), Congressionally Directed Medical Research Program (CDMRP) that will enable the research community to (1) improve the scientific understanding of pathobiology from toxic exposures, (2) more efficiently assess comorbidities, and (3) accelerate the development of treatments, cures, and preventions. This is a fiscal year 2022 (FY22) funding opportunity.
The DoD TERP TRA supports translational research that will accelerate the movement of promising ideas in toxic exposure research into clinical applications, which include health care products, interventions, technologies, and/or clinical practice guidelines.
Deadline: November 3, 2022 at 5:00 p.m. ET
|
|
|
Toxic Exposures Research Program (TERP), Clinical Trial Award (CTA)
Award: $1.5M total in direct costs (with Partnering Principal Investigator Option - $2.5M total in direct costs)
The TERP is a new Department of Defense (DoD), Congressionally Directed Medical Research Program (CDMRP) that will enable the research community to (1) improve the scientific understanding of pathobiology from toxic exposures, (2) more efficiently assess comorbidities, and (3) accelerate the development of treatments, cures, and preventions. This is a fiscal year 2022 (FY22) funding opportunity.
The DoD TERP CTA supports the rapid implementation of clinical trials with the potential to improve the prevention, treatment, and/or management of symptoms, diseases, and/or conditions associated with or resulting from toxic exposures. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (e.g., drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.
Deadline: November 3, 2022 at 5:00 p.m. ET
|
|
|
National Cancer Institute (NCI), Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. NCI intends to commit $9M in FY2023, FY2024, and FY2025 to fund up to 15 R01 applications per year.
This FOA supports the CMSDP and solicits R01 grant applications that propose independent research projects that reflect the scientific mission of the NCI. The goal of the CMSDP is to increase the number of R01 Early-Stage Investigators, enhance the diversity of the cancer research workforce, and promote scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups (see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply.
Deadline: November 8, 2022
|
|
|
MD22-008 Understanding and Addressing Misinformation among Populations That Experience Health Disparities (R01 Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
This grant will support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
|
|
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional)
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI Informatics Technology for Cancer Research (ITCR) program targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
Melanoma Research Alliance (MRA) RFP for Team Science Awards That Target Patient-Centric Clinical Trials, Jointly Funded by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA
Award: $1.5 million
These awards will fund clinical trials with the potential to provide benefit to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of improving the well-being of melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, which includes planning and dissemination.
Letters of intent (LOI) due 11:59 p.m. ET, October 5, 2022
Estimated LOI decisions: November 18, 2022
Invited full proposals due 11:59 p.m. ET, January 18, 2023
|
|
|
Cancer Prevention-Interception Targeted (CAP-IT) Agent Discovery Program Centers
Award: Up to $1.2M/year for a maximum of 4 years
This FOA solicits applications for CAP-IT Centers (U54). The objective of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research that targets precision cancer prevention and interception, with the goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process among higher-risk populations.
Deadline: November 21, 2022 at 5:00 p.m. PT
|
|
|
Damon Runyon, Physician-Scientist Training Award
Award: Total of $460,000, distributed over 4 years
To confront the growing shortage of physician-scientists, the Damon Runyon Cancer Research Foundation wishes to encourage more physicians to pursue research careers. As such, the Damon Runyon Foundation has established a program designed to recruit outstanding U.S. specialty board eligible physicians to cancer research careers, by providing them with the opportunity for a protected research training experience, under the mentorship of a highly qualified and gifted mentor, after they have completed all of their clinical training. The goals of the program are to (1) transform these individuals into the highest quality physician-scientists, capable of conducting research that has the potential to transform the diagnosis, treatment, and/or prevention of cancer and (2) eliminate the financial disincentive of pursuing this career path.
Deadline: December 1, 2022 at 4:00 p.m. ET
|
|
|
Alex's Lemonade Stand 2023 Young Investigator Grant
This Young Investigator Grant is a 3-year award designed to support early-career researchers, such as postdoctoral fellows, clinical fellows, or instructors, who are pursuing promising childhood cancer research. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. The proposed project must include both a mentor and a career development plan.
This grant offers up to $50,000 in direct costs per year for 3 years.
Deadline: December 12, 2022 at 8:00 p.m. ET
|
|
|
Basic/Translational Research on Health Disparities among Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed).
NCI intends to commit $3.5M in FY 2023 to fund 7-10 awards and $3.5M in FY 2024 to fund another 7-10 awards.
Through this FOA, the NCI intends to address the biological interactions of cancer health disparities among people living with HIV (PLWH) from underrepresented minority groups, through basic mechanistic or translational studies, by understanding how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.
Application budgets are not limited yet must reflect the actual needs of the proposed project. The scope of the proposed project will determine the project period. The maximum project period is 5 years.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
|
|
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)
The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.
Through this FOA, the NCI intends to address the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups, through basic mechanistic or translational studies, by investigating how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
|
|
Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
The Damon Runyon Cancer Research Foundation, Clinical Investigator Award supports independent young physician-scientists who conduct disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists who strive to improve the practice of cancer medicine.
Through this award, the awardee will receive not only financial support for 3 years, but also assistance with certain research costs, such as the purchase of equipment. The Damon Runyon Foundation also will retire up to $100,000 of any medical school debt still owed by the awardee.
The Clinical Investigator Award program is intended to provide outstanding young physicians with the resources and training structure essential to becoming successful clinical investigators. The goal of the program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside, in search of breakthrough treatments.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years.
Through this FOA, the NCI, along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing secondary data analysis and integration of existing datasets and database resources, with the aim of elucidating the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, and response to treatment). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
NIH R01 Standard Due Dates Apply
Next Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
Application budgets are limited $500,000 direct costs per year. The maximum project period is 5 years.
Through this FOA, the NCI and the National Institute on Drug Abuse (NIDA) will support a coordinating center to facilitate coordination of research activities between the new Cooperative Agreements U01 awards supported under the companion RFA-CA-22-052.
The coordinating center will have several responsibilities, which include, but are not limited to, providing logistical and administrative support to the U01 awards supported under the companion RFA-CA-22-052. Center responsibilities will involve working with the U01 awardees to (1) facilitate sharing of data collection instruments, measures, and resources and (2) identify a core set of questions to be included in data collection across the funded studies. The center will create standard operating procedures and ensure best practices are followed for data and biospecimen collection and analytical assays. The center also will facilitate communication across cohorts, coordinate topical working groups around key scientific issues that cut across individual U01 projects, provide meeting support, create and maintain a project website, and facilitate deposition of data to NIH repositories.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
Application budgets are limited to $500,000 direct costs per year. The maximum project period is 5 years.
Through this FOA, the NCI, the National Institute on Drug Abuse (NIDA), and the National Center for Complementary and Integrative Health (NCCIH) invite Cooperative Agreement (U01) applications that propose prospective research studies to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors currently receiving treatment. Studies are expected to compare cancer patients who use cannabis/cannabinoids with cancer patients that do not use cannabis and/or cannabinoids.
Research studies including diverse populations by age, sex, race/ethnicity, tumor types, and/or geography and propose population-based recruitment strategies using cancer registries are strongly encouraged.
This FOA is published in parallel with RFA-CA-22-053 "Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed).” New prospective studies and the coordinating center funded under these FOAs will work together with NIH program staff.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
|
Pfizer-Cell Signaling, San Diego Postdoctoral and Graduate Fellowships
Postdoctoral Fellowship - $70,000 for postdoc salary and benefits
Graduate Fellowship - $46,000 for tuition in full and balance towards stipend
We are delighted to announce a new partnership with Pfizer Oncology to support one postdoctoral fellow and one graduate student for up to 2 years. Please see the RFA link below. The deadline to receive application materials (as a single PDF) is Monday, November 28, 2022. We encourage submissions from postdocs and graduate students in your labs who are working in the area of cell signaling and oncology. This is a remarkable opportunity for trainees to interact with the Pfizer Oncology team in La Jolla.
Deadline: November 28, 2022
|
|
|
We are offering the following discounted rates for UCSD Fellows and Faculty. To register, please visit https://na.eventscloud.com/oncology2022.
$50 Fee for Fellows use code: FELLOW50
$75 Fee for Faculty use code: FACULTY75
|
|
|
Join Us In-Person at SITC 2022
37th Annual Meeting and Pre-Conference Programs
Tuesday to Saturday, November 8-12, 2022
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
|
|
|
Saturday, January 28, 2023
|
|
|
Newly Opened Clinical Trials
|
|
|
| CTO Staff of the Month - October 2022
Congratulations to Vanessa Sanchez for being recognized by her peers for her dependability, proactiveness, and ability to problem-solve independently. Vanessa is being praised for her continuous professionalism, her reliability, and responsiveness. Her colleagues always can count on her to answer questions quickly and help find answers promptly. Vanessa is an asset to the Finance Team and to the Clinical Trials Office. Thank you, Vanessa!
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
| Biobehavioral Shared Resource
The overarching goal of the Biobehavioral Shared Resource (BBSR) is to enhance the feasibility and success of MCC investigators studying not only lifestyle behaviors and effect of interventions, but also biological indicators of cancer outcome, to reduce cancer risk and increase survival following the diagnosis of cancer. The BBSR provides expertise and guidance in developing and operationalizing behavioral research for MCC members who either do not have expertise in these areas or who have limited resources to use high-quality, science-based methodology without the context and efficiency of a consolidated service core.
The BBSR provides the following services:
|
-
Biological indicators assessment, which includes development of biological specimen processing protocols plus direct services for sample collection (e.g., phlebotomy) and processing (e.g. DNA & RNA extraction and small scale genotyping), instrument use (e.g. QiaCube), and laboratory analysis conducted in-house or by outside laboratories.
-
Behavioral assessment (e.g., dietary intake, physical activity, body composition), which includes protocol development plus direct services, such as providing devices, conducting dietary recalls and questionnaires, training, and processing of data.
-
Behavioral intervention services, which includes guidance on design and content for weight loss, diet and physical activity interventions, protocol development, training, and guidance with new communication modalities.
|
The BBSR collaborates with the UCSD Exercise and Physical Activity Resource Center (EPARC), which facilitates the use of subsidized, accessible services relating to physical activity, fitness, strength, and body composition.
BBSR laboratory instrumentation and methodologies enable analysis of nutrients and dietary biomarkers in biological samples that are not generally available through clinical laboratories. Biological samples may include blood, urine, saliva, cell culture media, products, and formulations.
The BBSR not only provides services to members of other NCI Comprehensive Cancer Centers, but also supports clinical research projects conducted by NCI-supported cooperative groups.
CONTACT US FOR MORE INFORMATION
Laboratory biological indicators assessment and sample collection: Brinda Rana, Ph.D. (bkrana@ucsd.edu)
Dietary intake assessment and intervention services: Cheryl Rock, Ph.D., R.D. (clrock@ucsd.edu) and Christine Zoumas, M.S., R.D. (czoumas@ucsd.edu)
Physical activity, fitness, strength, and body composition assessment: David Wing, M.S. (dwing@eng.ucsd.edu)
|
|
|
-
Long T, Abbasi N, Hernandez JE, Li Y, Sayed IM, Ma S, Iemolo A, Yee BA, Yeo GW (SFG), Telese F, Ghosh P (CBS), Das S (CBS), Huang WJM (CBS). RNA binding protein DDX5 directs tuft cell specification and function to regulate microbial repertoire and disease susceptibility in the intestine. Gut. 2022 SEP 01; 71(9):1790-1802.
-
Weitz J, Hurtado de Mendoza T, Tiriac H, Lee J, Sun S, Garg B, Patel J, Li K, Baumgartner J (STT), Kelly KJ, Veerapong J, Hosseini M, Chen Y (CBS), Lowy AM (STT). An ex-vivo organotypic culture platform for functional interrogation of human appendiceal cancer reveals a prominent and heterogenous immunological landscape. Clin Cancer Res. 2022 SEP 06; CCR-22-0980.
- Xin B, Yang M, Wu P, Du L, Deng X, Hui E (HEM), Feng GS (CBS). Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology. 2022 SEP 01; 76(3):630-645.
-
Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, González A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP (STT), Bashan A, Swafford AD, Pilpel Y, Knight R (SFG), et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 SEP 29; 185(20):3789-3806.e17.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to the newsletter, please utilize the submission form link below.
Please direct any questions to our Marketing and Communications Coordinator, Sarah Christie, at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the Moores Cancer Center newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the website. Please provide us with the data we need to showcase your great work by completing the Member Survey linked below.
Thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to schristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|